SCHEMBL3669063

SCHEMBL3669063

Cc1nc(N)sc1-c1csc(CN(C)C)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.50
KMT2A Q03164 13/20 0.50
MAPT P10636 9/20 0.50
NPC1 O15118 8/20 0.50
GAA P10253 8/20 0.50
ALDH1A1 P00352 7/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
HSD17B10 Q99714 6/20 0.50
LMNA P02545 4/20 0.50
HPGD P15428 3/20 0.50
MAPK1 P28482 2/20 0.50
ALOX12 P18054 1/20 0.50
HTT P42858 2/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
KDM4E B2RXH2 3/20 0.47
USP2 O75604 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
POLB P06746 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3661766 0.83 LMNA (0.51) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2835237 0.78 LMNA (0.46) MEN1KMT2AMAPTNPC1GAA
SCHEMBL3668759 0.77 PIK3CA (0.53) MEN1KMT2AMAPTNPC1GAA
SCHEMBL3511497 0.76 MEN1 (0.64) MEN1KMT2AMAPTNPC1GAA
SCHEMBL11155374 0.72 CNR2 (0.52) MEN1KMT2AMAPTNPC1GAA
SCHEMBL3510926 0.71 LMNA (0.53) MEN1KMT2AMAPTNPC1GAA
SCHEMBL3511268 0.70 PIK3CA (0.58) MEN1KMT2AMAPTNPC1GAA
SCHEMBL16500126 0.70 MEN1 (0.65) MEN1KMT2AMAPTNPC1GAA
SCHEMBL25920835 0.70 MEN1 (0.61) MEN1KMT2AMAPTNPC1GAA
SCHEMBL3512954 0.70 LMNA (0.47) MEN1KMT2AMAPTNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940771-B2 Organic compounds NOVARTIS AG (CH) 2015-01-27 US disclosed
EP-2240475-B1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS NOVARTIS AG (CH) 2013-09-25 EP disclosed
EP-2240475-A1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS Novartis AG (CH) 2010-10-20 EP disclosed
EP-2238134-A2 BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2010-10-13 EP disclosed
WO-2009080694-A1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS NOVARTIS AG (CH) 2009-07-02 WO disclosed
WO-2009080705-A2 BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2009-07-02 WO disclosed
US-20090163469-A1 Organic Compounds NOVARTIS AG 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163469-A1 Organic Compounds PIK3C3, PIK3CA, PIK3CD MEN1 1564/4885KMT2A 4193/4885MAPT 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.